

Methodological Note

Abcur AB (An entity of Advanz Pharma) located in Sweden is committed to ensuring transparency of relationships with healthcare professionals (HCPs), healthcare organisations (HCOs), patient organisations (POs), by operating within the "Läkemedelsindustriföreningen (Lif)" aligned with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code, International trade association IFPMA as well as of the Association of the European Self-Medication Industry (AESGP) on Disclosure of Transfers of Value.

Transfers of Value (ToV) i.e. payments or benefits received by HCPs, HCOs, POs during the 2023 calendar year will be disclosed on the ADVANZ PHARMA Ethics and Transparency page: <https://www.advanzpharma.com/ethics-and-transparency> and made public on 30th June 2024

The principles applied in this methodological note are relevant to Sweden only.

Definitions

- "Healthcare Professional (HCP)": A member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his/her professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product and whose primary practice, principal professional address or place of incorporation is in Sweden.

If an HCP has set up a private company, as a sole director, they will be considered an HCP for disclosure purposes. Part-time employees or contractors of Abcur AB (including employees or contractors of Abcur AB appointed agencies and third-party vendors) who are not also an employee of an HCO would fall outside the scope of disclosure for ToVs made by Abcur AB. For example, if an employee or contractor is providing full time services to ADVANZ PHARMA (or to Abcur AB appointed agencies or third-party vendors) and they are not also employed by an HCO then this would not be considered as reportable.

- "Healthcare Organisation (HCO)": A healthcare, medical or scientific association or organisation (e.g., a hospital, clinic, foundation, university or other teaching institution or learned society) whose business address, place of incorporation or primary place of operation is in Sweden; or an organisation through which one or more HCPs provide services.
- "Patient organization (PO)": An organisation mainly comprising of patients and/or caregivers or any user organisation such as a disability organisation, carer or relative organisation and consumer organisation that represents and/or supports the needs of patients and/or caregivers.
- "Research and Development (R&D)": HCP/HCO transfers of value that relate to the planning and conduct of:
 - Non-clinical studies (as defined in OECD Principles on Good Laboratory Practice);
 - Clinical trials (as defined in Directive 2001/20/EC);
 - Non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study. This also includes investigator sponsored research (ISRs).

Disclosure Categories

In 2023 Abcur AB has disclosed the following financial & non-financial payments:

	Example activities	HCP	HCO	PO
<u>Contracted Services</u> ToVs resulting from or related to a contract where the HCP / HCO/ PO provides services.	Advisory Boards Speaker Services Consulting Services Steering Committees Market Access / Market Research*	?	?	?
<u>Related expenses to the contracted service</u> ToVs directly related to a fee for service contract**.	Travel (incl. flights, taxi, train, parking) Accommodation	?		?
<u>Sponsorship agreements</u> ToVs made to either the HCO/PO directly or to an event organizer or other third party appointed by the HCO/PO to manage an educational or scientific event.	Congress sponsorship Stand / booth sponsorship		?	?
<u>Support to attend third party led educational meetings</u>	Registration Fees	?	?	
	Travel & Accommodation	?		
<u>Donations**</u> Non-financial support provided for an unspecified purpose.	Donations		?	?
<u>Grants**</u> Funding provided to support a specific activity that provides educational benefit or enhances patient care.	Grants		?	?
<u>Research and development</u> ToVs related to non-clinical studies, clinical studies and non- interventional studies.	Investigator site fees Advisory boards related to R&D Expert meeting services Data safety monitoring boards Steering Committee meetings Investigator sponsored research	?	?	
<u>Benefits in kind</u>	AVEP Provision of free passes to educational events	?	?	?

* Market access and market research costs where the identify of the individual is known to Abcur AB, where these activities are “blind” or unknown to Abcur AB, these disclosures are not made.

** Donations and grants for medical educational projects. Abcur AB funding policies in these circumstances require that Abcur AB has no influence over the details of the project. As Abcur AB would not influence or select HCPs involved in such projects, Abcur AB would disclose such payments under an HCO category where such definition is met by the independent company. Where Abcur AB is requested by an HCO to provide a financial grant to assist its employees to attend third party medical meetings, where possible the payment will be disclosed against a named individual HCP. Where Abcur AB is not aware of the identity of recipient HCPs, the grant is declared against the named healthcare organisation.

The following categories were deemed out of scope for disclosure:

1. All costs associated with meetings run solely by Abcur AB except for fees paid to individual HCPs providing services as speakers;

2. All costs associated related to OTC medicines and Medical Devices.
3. All costs associated to meals and subsistence
4. All delivery of samples
5. All articles of medical utility and educational or informative materials to HCPs

Data Privacy & Consent Methodology

Abcur obtains consent from HCPs in the HCP engagement agreements to disclose personal data related to individual transfers of value and publishes individualized data accordingly. Where permission has not been obtained or where HCPs have refused consent, Abcur may declare an aggregate figure given on a separate line entry within the relevant disclosure category and the % of non-consenting HCPs given as a percentage of the total HCPs receiving a ToV. HCPs have the right to withdraw consent at any time. If Abcur receives such a withdrawal of consent, Abcur will, within a reasonable period, move the relevant ToV data into the aggregate category.

HCO and PO consent is not required in order to disclose ToVs against named organisations in the Sweden.

Research and development will be disclosed in aggregate for all Sweden transfers of value.

ToV Transaction Principles

Payments to Third Party Organisations for Services Provided by Individual HCPs

In some cases Abcur AB contracts with HCPs through a third party agency. In such cases, Abcur AB will disclose any payments made to the individual HCP by the service agency as if the payment had been made directly by Abcur AB to that HCP.

VAT & Fees

For all ToVs, VAT and other applicable taxes and business-related fees (e.g. administration fees) are excluded.

Transaction Date

ToVs are reported based on payment date or transfer of value date (e.g. the date a flight was taken). Where an interaction with an HCP, HCO, or PO runs for more than one year, Abcur AB will disclose ToVs made in the year of payment or transfer.

Transfer in foreign currencies

Abcur AB discloses ToVs in Swedish Krone (SEK). Where ToVs are made in another currency, the invoice amount will be converted into Swedish Krone (SEK) using a monthly exchange rate. Amounts disclosed may therefore vary slightly from the exact amounts paid.

Cross-Border Payments

All disclosures are made in the country in which the HCP or HCO practice is located. Payments made to Germany-based HCPs or organisations by Abcur AB overseas operations are disclosed within Germany.

Cancellations and non-participation

ToVs will only be disclosed where the benefit has been received. In the event of a cancellation or where an HCP, HCO, or PO does not receive the benefit due to non-participation, Abcur AB will not disclose ToVs against such HCP, HCO or PO.

Co-Marketing Projects

Where Abcur AB jointly markets a product with another pharmaceutical company, Abcur AB will only declare those payments made directly from Abcur AB bank accounts and listed in the company records as part of its normal business operations. Transfers of value made by its co-marketing partners will be disclosed separately by those organisations.

Disclosure Principles

Additionally, Transfer of Value above are disclosed on the ADVANZ PHARMA Ethics and Transparency page: <https://www.advanzpharma.com/ethics-and-transparency> and made public on 30th June 2024

The disclosure of transfers of value to a PO must include both the monetary value and a description of that support to enable the reader to understand the nature of that support or the arrangements.

ADVANZ PHARMA will maintain public disclosures for a minimum of three (3) years and will retain records for at least five (5) years after the end of the calendar year to which they relate.